Glide Pharma has entered into an agreement with Nypro Healthcare, a global device manufacturer, to complete the design optimisation of its solid dose injector in preparation for production scale up. The company’s delivery system, the Glide SDI, is a unique technology for injecting drugs and vaccines in a solid dosage form without the need for a needle.

The Glide SDI comprises a novel tiny solid dosage, which is pushed into the skin with a small, hand-held, spring-powered device. Nypro Healthcare will work with Glide Pharma to ensure the design of the device and its components are optimised for manufacturing scale up and to ensure patient requirements, including self-administration, are met.

“This agreement marks a milestone for our Glide SDI device as it will enable us to complete the final phase of development prior to production scale up. As a recognised leader in the development and manufacturing of precision devices we believe that Nypro Healthcare is the perfect partner to work with Glide Pharma on advancing our novel delivery system,” stated Dr Mark Carnegie-Brown, CEO, Glide Pharma.

“The Glide SDI is a highly innovative delivery system, which is very different from other technologies currently on the market. Nypro Healthcare is delighted to have been selected as Glide Pharma’s partner to help progress the development of this exciting new technology,” commented Chris Nother, VP Business Development, Nypro Healthcare.

Nypro Healthcare is a provider of device development and global manufacturing services to the world’s leading and emerging pharmaceutical, diagnostics and medical device companies, supporting from concept, through clinical trials and into commercial production.